We describe the results of a molecular epidemiological survey of 15 carbapenemase-encoding genes from a recent collection of clinical isolates from Mercy Hospital in Bo, Sierra Leone. The most salient findings revealed that (i) 60% of the isolates harbored multiple carbapenemase genes; (ii) the bla DIM-1 gene, which has previously only been reported in The Netherlands, is also circulating in this environment; and (iii) bla OXA-51-like and bla OXA-58 genes, which were thought to reside exclusively in Acinetobacter species, can also be found in members of the Enterobacteriaceae.
C arbapenem antibiotics are currently the most potent ␤-lactam antibiotics clinically available and are used as a last resort to treat infections caused by multidrug-resistant Gram-negative pathogens. The significance and usage of this family of antibiotics have risen dramatically over the last decade, especially in hospital settings, due to the global spread and increasing prevalence of bacterial pathogens that harbor extended-spectrum ␤-lactamase genes that confer resistance to all ␤-lactam compounds except for carbapenems (1) . Not surprisingly, the positive selection pressure provided by the increased usage of carbapenems has resulted in the emergence and expansion of carbapenem resistance in a number of common nosocomial pathogenic species (1) .
Carbapenem resistance is mediated mostly by ␤-lactamase enzymes that are capable of hydrolyzing carbapenem compounds (carbapenemases) and often differ in host microorganism range, substrate specificity, and ␤-lactamase inhibitor sensitivity (2, 3) . Furthermore, carbapenemases are frequently found in pathogenic strains that contain additional genetic determinants that confer resistance to aminoglycosides, tetracyclines, ␤-lactams, and fluoroquinolones and can result in intractable infections with high mortality rates (4, 5) . The spread of Ambler class A, B, and D carbapenemase genes, which were encountered only rarely less than 2 decades ago, has been facilitated by conjugative plasmids, transposons, and integrons to such an extent that carbapenemase genes have now been reported worldwide (2) . Despite this fact and the clinical impact of these genes, the true incidence and prevalence of carbapenem resistance and carbapenemase genes are still unknown, as many countries do not track and report antibiotic resistance rates; this is particularly true in many African countries (1) .
To better understand the level, distribution, and evolution of multidrug resistance in environments that currently lack a national antibiotic stewardship policy, we initiated a molecular epidemiology surveillance program at Mercy Hospital in Bo, Sierra Leone. The preliminary evidence, obtained using an antimicrobial resistance determinant microarray as a screening tool (6) , indicated the presence of class B metallo-␤-lactamase (MBL) and class D carbapenem-hydrolyzing ␤-lactamase (CHDL) genes in this environment. In this study, we utilized PCR and DNA sequencing to target 15 carbapenemase genes (bla OXA-23 , bla OXA-24 , bla OXA-48 , bla OXA-51-like , bla OXA-58-like , bla AIM , bla BIC , bla DIM , bla GIM , bla IMP , bla KPC , bla NDM , bla SIM , bla SMP , and bla VIM ) from a recent collection of Mercy Hospital isolates to better understand the carbapenemase content of actively circulating strains. Ethical approval was obtained from the Njala University Institutional Review Board. All clinical samples were obtained from Mercy Hospital as preexisting diagnostic specimens that had been stripped of all identifiers. The Gram-negative clinical isolates analyzed (n ϭ 20) were collected from November 2010 to April 2011 on agar media and then identified based on PCR amplification and sequencing of a 16S rRNA gene amplicon that spanned the V3 and V4 variable regions (7) and of the rpoB and/or gyrA gene, as previously described (8, 9) . For a preliminary identification, the obtained 16S rRNA gene sequences were used to classify each isolate by using the naive Bayesian classifier available through the Ribosomal Database Project (release 10) (http://rdp.cme.msu.edu/classifier /classifier.jsp), with Ն80% confidence as the identification threshold (10) . This analysis identified 70% of the isolates as members of the Enterobacteriaceae, with the remaining isolates belonging to the Pseudomonadaceae, Burkholderiaceae, or Comamonadaceae. Secondary identifications based on rpoB or gyrA gene sequencing not only confirmed the 16S rRNA gene identifications but also provided genus-and species-level resolution to reveal well-known nosocomial pathogens (Enterobacter cloacae, Escherichia coli, and Klebsiella pneumoniae). In addition, the genomic DNA from one strain (SL-1) was subjected to low-pass whole-genome sequencing using an Illumina HiSeq 2000 sequencer (Illumina, San Diego, CA), and the assembled and annotated draft sequences were mined for carbapenemase genes and their flanking regions.
Targeted PCR analyses were performed using previously described primers and conditions (11, 12) , and selected amplicons were sequenced for allele confirmation. Importantly, 11 of the 15 targeted carbapenemase genes (bla OXA-23 , bla OXA-24 , bla OXA-48 , bla AIM , bla BIC , bla GIM , bla IMP , bla KPC , bla NDM , bla SIM , and bla SMP ) were not detected in any of the isolates tested. However, the remaining targeted Ambler class B (bla VIM and bla DIM-1 ) and D (bla OXA-51-like and bla OXA-58-like ) carbapenemase genes were detected and codetected in a surprising number of strains (Table 1 ). In fact, 60% of the tested isolates harbored multiple carbapenemase genes.
Perhaps even more surprising was the detection of the bla OXA-58-like and bla OXA-51-like CHDL genes in 85% and 40% of the isolates, respectively, as these genes were thought to reside exclusively in Acinetobacter species. While bla OXA-58-like genes are known to reside on conjugative plasmids in Acinetobacter spp., the bla OXA-51-like genes have been considered exclusively chromosomally encoded, intrinsic oxacillinase genes of Acinetobacter baumannii and are used by many investigators for species identification and strain typing (2, 13, 14) . However, a number of recent reports indicate that the bla OXA-51-like genes have been mobilized and are spreading to other Acinetobacter spp. by conjugative plasmids (15, 16) . Our findings bolster this contention and corrobo-rate a recent meeting abstract that describes the presence of bla OXA-51-like and bla OXA-58-like genes in Klebsiella pneumoniae and Escherichia coli isolates, respectively (17) . Furthermore, an analysis of the SL-1 draft genome sequence identified this strain as an Enterobacter cloacae isolate that harbored a complete bla open reading frame surrounded by flanking sequences that were 100% identical to ISAba3, found in a number of Acinetobacter plasmids (GenBank accession no. KC004135). Taken together, the results demonstrate the presence of the bla OXA-58 and bla OXA-51-like carbapenemase genes in non-Acinetobacter Gram-negative genera and suggest that these genes should no longer be considered genetic determinants that can be used for the specific identification of Acinetobacter species.
The bla OXA-51-like genes were detected in eight isolates ( Table  1) . Previously published primers (primers OXA-51-likeF and OXA-51-likeR [12] and primers 5=OXA-51-like-all-F and 3=OXA-51-like-all-R [18] ) were used to amplify and sequence these genes for allelic identification and to determine the presence of flanking ISAba1 sequences (using primers ISAba1F [18] and OXA-51-likeR). The obtained sequences were screened against a database of Ͼ80 currently known bla OXA-51-like genes, and a total of five different bla OXA-51-like variants were found (see Fig. S1 in the supplemental material). Nearly full-length sequences (94% of the entire gene) of the bla OXA-51-like variants revealed the presence of OXA-64 (strain SL-1), OXA-65 (strain SL-5), and OXA-98 (strains SL-9, SL-13, SL-14, and SL-15) genes. For two of the strains (SL-11 and SL-12), it was only possible to amplify and sequence ϳ30% of the gene. Although greater sequence coverage is needed for unambiguous identification of these variants, the obtained sequence information was sufficient to determine that the bla OXA-51-like gene in SL-11 contained a novel combination of single nucleotide polymorphisms (SNPs) that warranted its classification as a new variant of the OXA-71 gene. The same amount of sequence information also revealed that the bla OXA-51-like gene found in strain SL-12 matched either the OXA-71 or OXA-241 gene. ISAba1 insertion sequences were detected in each of the bla OXA-51-like gene-containing isolates, but they were not found flanking the bla OXA-51-like genes. Similar analyses were performed to determine the allelic identity of the 16 bla OXA-58-like genes that were detected in these isolates. Only two different sequence variants were identified, with one present in strains SL-1 and SL-11 and the other in all of the remaining positive samples. The variants differed by two SNPs (see Fig. S2 ), both of which generated silent mutations. The deduced amino acid sequences for both variants were identical and matched exactly with the OXA-58 sequence. In addition to the CHDL genes, two MBL genes were also identified among the tested isolates. Sixty percent of the isolates carried identical bla VIM sequences (which, based on the amplicon sequence, were consistent with bla VIM-2 or four other, less frequently observed variants: bla VIM-10 , bla VIM-16 , bla VIM-17 , and bla VIM-30 ), and 40% of the isolates were found to contain bla DIM-1 . While bla VIM (and especially bla VIM-2 ) is acknowledged as one of the most commonly isolated MBLs in Africa and throughout the world (19) (20) (21) (22) , the presence of bla DIM-1 has been reported only once before, for a Pseudomonas stutzeri isolate from The Netherlands (23) . In this study, bla DIM-1 was found in hospital isolates belonging to the families Enterobacteriaceae, Pseudomonadaceae, Burkholderiaceae, and Comamonadaceae. Importantly, the complete bla DIM-1 gene sequence was also found within the SL-1 draft genome and was found to be flanked by sequences consistent with a type 1 integron (GenBank accession no. KC004136).
In this study, we have presented the first molecular epidemiological survey of carbapenemase genes in West Africa. With respect to antimicrobial resistance determinants, this is a wholly uncharacterized environment. It is also an especially challenging environment in that the lack of surveillance coincides with easy over-the-counter access to the most commercially available antibiotics, little to no usage oversight, low-level awareness of infection control practices, and the absence of a national antibiotic stewardship policy. To begin to ascertain whether these factors may have played a role as the selection pressure that led to these findings, we conducted a voluntary survey of 15 independent pharmacies and 5 hospital dispensaries (including Mercy Hospital) to determine the availability of antimicrobial compounds in Bo, Sierra Leone. While none of the hospital dispensaries issued antibiotics without a prescription, 87% of the pharmacies that had access to the same collection of antibiotics as the hospital dispensaries acknowledged readily dispensing antimicrobial drugs without a prescription. Interestingly, none of the survey participants acknowledged issuing the carbapenem antibiotics imipenemcilastatin, meropenem, ertapenem, and doripenem, and the availability and use of carbapenem antibiotics have not previously been reported for this region. However, ␤-lactam antibiotics such as amoxicillin, ampicillin, cloxacillin, and, to a lesser extent, penicillin, cefuroxime, and ceftriaxone were readily issued (as were antibiotics from other classes, such as chloramphenicol, ciprofloxacin, clarithromycin, cotrimoxazole, doxycycline, erythromycin, metronidazole, gentamicin, rifampin, tetracycline, ofloxacin, and nitrofurantoin). Overall, the survey suggested that antibiotics in general are available and in use for self-treatment without a prescription or any professional supervision. Thus, while the selection pressure for the maintenance of the carbapenemase genes identified in this study does not appear to be due to the indiscriminate use of carbapenem antibiotics per se, it is possible that these alleles are maintained in this population due to the use of ␤-lactam antibiotics or their genetic linkage to other elements that may provide a more direct selective advantage. Furthermore, similar queries of antibiotic usage for veterinary medicine and food animal production have not been conducted in this environment and thus cannot be dismissed as the source of such selection pressure.
The serious implications of the dissemination of carbapenemase genes has led to the assertion that the early identification of strains containing these molecular determinants is necessary for effective infection control measures and informed therapeutic options (4, 24) . Although it cannot be presumed that the presence of class D carbapenemase genes within genetic backgrounds other than Acinetobacter will result in high resistance to carbapenem antibiotics (13, 25, 26) , these findings clearly demonstrate a broadening reservoir for these resistance determinants. Taken together and considering the needs, resources, and level of existing characterization of this environment, our findings warrant the continued use of molecular tools to better understand the scope, severity, and evolution of carbapenemase gene circulation and multidrug resistance in this part of the world.
Nucleotide sequence accession numbers. Newly determined nucleotide sequences have been deposited in GenBank under accession numbers KC004135 and KC004136.
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T C T AC AGAA A T A T T T A AG T GGGA T GGAA AGC C ACG T T T T T T T AA AGC A T GGGA C A AAGA T T T T A C T T T GGGCGA AGC CA T GC A AGC A T C T AC AG T GCC T G T A T A T C AAGAA T T GGCA CG T CG T A T T GG T C C A AGC T T A A T GCA A AG T GAA 351 SL1 T C T AC AGAA A T A T T T A AG T GGGA T GGAA AGC C ACG T T T T T T T AA AGC A T GGGA C A AAGA T T T T A C T T T GGGCGA AGC CA T GC A AGC A T C T AC AG T GCC T G T A T A T C AAGAA T T GGCA CG T CG T A T T GG T C C A AGC T T A A T GCA A AG T GAA 351 SL4 T C T AC AGAA A T A T T T A AG T GGGA T GGAA AGC C ACG T T T T T T T AA AGC A T GGGA C A AAGA T T T T A C T T T GGGCGA AGC CA T GC A AGC A T C T AC AG T GCC T G T A T A T C AAGAA T T GGCA CG T CG T A T T GG T C C A AGC T T A A T GCA A AG T GAA Consensus 100%
0%
Conservation
T T GCA A CG T A T T GG T T A T GGC A A T A T GC A AA T AGGCA CGGA AG T T GA T CA A T T T T GG T T GA AAGGGC C T T T GA C AA T T A C AC C T A T A CA AGA AG T A AAG T T T G T G T A T GA T T T AGCC C A AGGGC A A T T GC C T T T T AA A CC T GA AG T T C AG
T T GCA A CG T A T T GG T T A T GGC A A T A T GC A AA T AGGCA CGGA AG T T GA T CA A T T T T GG T T GA AAGGGC C T T T GA C AA T T A C AC C T A T A CA AGA AG T A AAG T T T G T G T A T GA T T T AGCC C --------------------------------469 SL1 T T GCA A CG T A T T GG T T A T GGC A A T A T GC A AA T AGGCA CGGA AG T T GA T CA A T T T T GG T T GA AAGGGC C T T T GA C AA T T A C AC C T A T A CA AGA AG T A AAG T T T G T T T A T GA T T T AGCC C --------------------------------469 SL4 T T GCA A CG T A T T GG T T A T GGC A A T A T GC A AA T AGGCA CGGA AG T T GA T CA A T T T T GG T T GA AAGGGC C T T T GA C AA T T A C AC C T A T A CA AGA AG T A AAG T T T G T -T A T GA T T T AGCC C A AGGGC A A T T GC C T T T T AA A CC T GA AG T T C AG Consensus
100% 0% AA The amplicons of bla OXA-58 genes were sequenced in both directions, trimmed to the equal length and aligned together with reference bla OXA-58 gene (accession no. AY665723). Only one sequence for each variant was selected for alignment. The aligned fragments span a gene fragment that corresponds to nucleotide positions 100 to 568 (approximately 56%) of the bla OXA-58 gene. Single nucleotide polymorphisms (SNPs) in sequences of detected variants are highlighted using red font, a dash "-" in consensus sequence and lower bars in histogram below sequence alignment.
Conservation
CA A CA AG T GA AAGAGA T G T T G T A T G T AGAGCGCAGAGGGGAGAA T CG T C T A T A T GC T A AA AG T GGC T GGGGAA T GGC T G T AGA CC CGCA AG T GGG T T GG T A T G T GGG T T T T G T T GAA A AGGC AGA T GGGC A AG T GG T GGC A T T T GC T T T A
G T T G T A T G T AGAGCGCAGAGGGGAGAA T CG T C T A T A T GC T A AA AG T GGC T GGGGAA T GGC T G T AGA CC CGCA AG T GGG T T GG T A T G T GGG T T T T G T T GAA A AGGC AGA T GGGC A AG T GG T GGC A T T T GC T T T A Consensus 100%
0%
Conservation
AA T A T GC AA A T GA AAGC T GG T GA T GA T A T T GC T C T ACG T AA A CA A T T G T C T T T AGA T G T GC T AGA T A AG T T GGG T G T T T T T C A T T A T T T A T A A
T A T GC AA A T GA AAGC T GG T GA T GA T A T T GC T C T ACG T AA A CA A T T G T C T T T AGA T G T GC T AGA T A AG T T GGG T G T T T T T C A T T A T T T A T A A Consensus
